Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Flow cytometric analysis of IL-21 receptor (CD360) in human peripheral lymphocytes. Whole blood was stained simultaneously with PerCP-CY™5.5 Mouse Anti-Human CD19 (Cat. No.340951) and APC Mouse Anti-Human IL-21 Receptor (CD360) (Cat. No. 560331; left panel) or APC Mouse IgG1, κ Isotype Control (Cat. No. 555751; right panel). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color dot plots depicting IL-21 receptor (CD360) (or Ig isotype control) versus CD19 expression were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCalibur™ System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The 17A12 monoclonal antibody specifically binds to the IL-21 Receptor (IL-21R). The IL-21R, also known as CD360, is a 538 amino acid cytokine receptor with an extracellular domain consisting of one copy of the conserved WSXWS -containing cytokine-binding domain. The IL-21 receptor combines with the common cytokine-receptor γ-chain to form a functional receptor complex for IL-21. IL-21 is mainly produced by activated CD4+ T cells including T follicular helper (Tfh) cells. IL-21R is preferentially expressed by B cells, T cells, NK cells, some populations of myeloid cells, keratinocytes, and dendritic cells. Binding of its ligand, IL-21, in these cells results in the activation of the Jak/Stat signal transduction pathway. The effects IL-21 ligand binding has pleiotropic actions such as augmenting the proliferation of T cells, driving of B cells into memory cells, terminally differentiating plasma cells and augmenting the activity of natural killer cells. IL-21 receptor has anti-tumor activity and might have a role in the development of autoimmunity; it has been reported that the IL-21 receptor affects the homeostasis of regulatory T cells and it could enhance T cell-activated responses in human immune-inflammatory diseases.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.